Unit | Clinical Immunology

Our group focuses on systems-immunology-based approaches within the framework of Phase I to III clinical trials. We aim to identify surrogates of protection as well as host factors elicited by subunit and whole parasite vaccines against tuberculosis (TB) and malaria. Clinical trials are performed with our partners of the Ifakara Health Institute in Bagamoyo. Further, the unit develops novel diagnostic tools for paediatric clinical TB in high endemic countries.


Co-morbidity studies analyse the impact of non-communicable diseases on immune responses against infectious diseases, particularly TB. Unit researchers also work to understand the consequences of helminth co-infections on malaria, TB and HIV pathogenesis and immunity.

Rutishauser T et al. Activation of TCR Vδ1+ and Vδ1-Vδ2- γδ T cells upon controlled infection with Plasmodium falciparum in Tanzanian volunteers. J Immunol. 2020;204(1):180-191. DOI: 10.4049/jimmunol.1900669

Amelio P et al. HIV infection functionally impairs Mycobacterium tuberculosis-specific CD4 and CD8 T-cell responses. J Virol. 2019;93(5):e01728-18. DOI: 10.1128/JVI.01728-18

Butt Y. Comparison of phenotypes and functional markers of Mycobacterium tuberculosis specific CD4 T cell responses for monitoring TB drug treatment and host directed therapy. Basel: Swiss Tropical and Public Health Institute, 2019. MSc

Dobaño C et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nat Commun. 2019;10:2174. DOI: 10.1038/s41467-019-10195-z

Hill D.L et al. The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRbeta clonotypes. J Exp Med. 2019;216(8):1857-1873. DOI: 10.1084/jem.20190301